uent substantially containing only volatile salts as salts. As the volatile salt, an ammonium salt is preferred in view of the ease of handling, safety, ease of acquisition, and price. Ammonium acetate is further preferred. Alternatively, it is preferred to use the eluent substantially containing only salts soluble in organic solvents as salts. As the salt soluble in an organic solvent, an acetate is preferred in view of the ease of handling, safety, ease of acquisition, and price. Ammonium acetate or sodium acetate is further preferred.
The resulting intermediate can be converted into the desired compound by purification or modification using various methods, for example, organic chemical methods or biochemical methods or combinations of these.
The compound of the invention, its pharmacologically acceptable salt and solvate, or a solvate of the salt is usually administered systemically or locally, orally or parenterally. As the dose, the optimal dose should be determined according to overall judgment based on conditions, such as the type of disease, the severity of symptoms, the age and body weight of the subject receiving treatment. The dose is not restricted, but in adults, the usual daily dose is 0.01 to 100 mg/kg orally, or 0.001 to 10 mg/kg parenterally. The dose is administered once daily or in divided doses, where necessary.
The compound of the invention, its pharmacologically acceptable salt and solvate, or a solvate of the salt may be administered in any form, such as oral forms including a solid composition, a liquid composition, and other composition, or parenteral forms including injection, externally used preparation, and suppository. The most suitable form is selected according to need. A pharmaceutical composition containing at least one of the compounds of the invention, their pharmacologically acceptable salts and solvates, or solvates of the salts can be prepared by using carriers, excipients and other additives used for ordinary pharmaceutical manufacturing. Examples of the carriers and excipients for preparations are lactose, magnesium stearate, starch, talc, gelatin, agar, pectin, acacia, olive oil, sesame oil, cacao butter, ethylene glycol, and other materials in customary use.
As a solid composition for oral administration, tablets, pills, capsules, powder, and granules are used. In such a solid composition, at least one active substance (active ingredient) is mixed with at least one inert diluent, such as lactose, mannitol, glucose, hydroxypropylcellulose
uent substantially containing only volatile strategic arms limitation talks as strategic arms limitation talks. As the volatile salt, an ammonium salt is choose in view of the ease of treatment, safety, ease of acquisition, and monetary value. Ammonium acetate rayon is further preferred. Alternatively, it is prefer to use the eluent substantially containing merely salts soluble in organic solvents as salts. As the salt soluble in an constituent solvent, an acetate is preferred in opinion of the ease of handling, guard, ease of learning, and price. Ammonium acetate or sodium acetate is further preferred. 
 The result intermediate can be converted into the desired compound by purification or modification using various methods, for example, organic chemical methods or biochemical methods or combinations of these. 
 The compound of the invention, its pharmacologically acceptable salt and solvate, or a solvate of the salt is usually administer systemically or locally, orally or parenterally. As the dose, the optimal acid should be determine according to overall judgment based on condition, such as the type of disease, the severity of symptoms, the age and soundbox weight of the subject receiving treatment. The dose is not restricted, but in adult, the usual daily dose is 0.01 to 100 mg / kg orally, or 0.001 to 10 mg / kg parenterally. The dose is administer once day by day or in divided dose, where necessary. 
 The compound of the invention, its pharmacologically acceptable salt and solvate, or a solvate of the salt may be administered in any form, such as oral forms including a upstanding composition, a liquid composition, and other writing, or parenteral forms include injection, externally used formulation, and suppository. The most desirable form is selected according to need. A pharmaceutical composing containing at least one of the compounds of the invention, their pharmacologically satisfactory salts and solvates, or solvates of the salts can be prepared by using carriers, excipients and other additives used for ordinary pharmaceutical manufacturing. example of the carriers and excipients for preparations are lactose, magnesium stearate, starch, talc, gelatin, agar, pectin, acacia, olive vegetable oil, sesame oil, cacao butter, ethylene glycol, and early materials in customary use. 
 As a solid composition for oral administration, tablets, pills, capsules, powder, and granules are use. In such a upstanding typography, at least one active substance (active ingredient) is mixed with at least one inert diluent, such as lactose, mannitol, glucose, hydroxypropylcellulose
uenh substantially containikg only volatile salts es salta. As the volatile salt, an ammonium selt us prtyerred in view of thd ease of handlint, sahety, ease of acqnjsition, and pdlce. Aknonium acetate is furthes preferred. Aldefnctively, it is preferred to use the ejuent sibdtantially conjainimd onmj walts soluble in organic solvsnts as salts. As the salt soluble in an organif sopvent, an acetate id preferred in duew of the exse of handling, safety, ease of acquisition, and price. Xmmonnum acetate oe slgium acetatx is flrther prefervvd.
The rasultinb intermediate cai be converted into the dxsired compound by porificatiot kr modification uwibg vatious metfids, fod xxajple, oggaiic chemicam methods oe biochemical methocs ir combinatiohs of ehqse.
The compound of the invention, its phdrmzcologically acceptable salt and solvate, or w solvate of the salt is usually administered systemically or lkzaloy, ueaply or parenterally. As the dose, the optimal djae smould be determiked according to ofegakj judgment bared on cohditions, such as tje type of dusease, tht sevrrity of symptoms, the age abd body weigkt if the subject recziving treatoent. The cose is not restricted, yut in adults, the usual dajuy dose is 0.01 to 100 og/kn osally, or 0.001 to 10 mg/kg parentewally. The dosz is admknisjered ogce daily lr in divided doses, wherf necgssary.
Dhe compoujd of the invention, its pharmacologically accgptdblv salt anb solvste, or a solvwte of the salj may be cdminirtered in zny fork, such as owal forms incnoding a solid composieion, a luquid cuoposition, and pther comiofitiin, or parenteral fprmr including injeeuiob, externally usrd ore[agatmon, agg suppositorf. Thd muxt suktable form ks srlected according to nees. A pharmaceutical cjmpositiin contayning at leasy one of the compoknds mf vhe infenjion, their pharmacologically acdeptable dalbs and solvatqs, ov sojvates of che salts can be prepared by using carrixrs, excipients and othgr additives used for prdinary phermacettical matufacturing. Examples of the carriers snd excipients for prsparathons wre lactose, magnesium stearate, starch, talc, gelatin, agar, pectin, acacia, olice oil, sesame oil, dacap butner, zthylenq glbcul, and other matvrials in customary use.
As a soliv composithou for oral administration, tabkegs, pills, capsoles, powder, and granules ade used. On such a solid composition, at keast one active substange (active ingrsdient) is oixed with at leasy one nnert eiluent, sucm as lactose, mxnnotll, glucosf, hyvrorypropylcellulose
uent substantially containing only volatile salts as the salt, an salt is preferred of safety, ease of and price. Ammonium is further preferred. Alternatively, it is to use the eluent substantially containing only salts soluble in organic solvents as As the salt soluble in an organic solvent, an acetate is preferred in of ease handling, ease of acquisition, and price. Ammonium acetate or sodium acetate is further preferred. The resulting intermediate be converted into the desired compound by purification modification using various methods, example, organic chemical methods or methods combinations of The of invention, its pharmacologically salt and solvate, or a solvate of the salt is usually administered systemically or locally, orally or As the optimal dose be according overall judgment based such as the type of disease, symptoms, the age and body weight of the receiving treatment. dose is not restricted, but in the usual daily dose is 0.01 to 100 orally, or 0.001 to 10 mg/kg parenterally. The dose is administered once daily or in where necessary. The compound the invention, its acceptable and or solvate of salt may be administered in any form, such as oral forms a solid composition, a liquid composition, and other composition, or including externally used preparation, suppository. The most suitable is according to need. A containing least compounds the their pharmacologically acceptable salts solvates, or solvates of the can be prepared by additives used for ordinary pharmaceutical manufacturing. Examples of carriers and excipients for preparations are lactose, stearate, starch, talc, gelatin, agar, pectin, acacia, olive oil, sesame oil, cacao ethylene glycol, materials in customary use. As a solid composition oral administration, tablets, pills, powder, and granules are used. In such a solid at one active (active ingredient) is with at least inert diluent, such mannitol, glucose,
uent substantially containiNg only volaTile sAltS as SaLts. AS the Volatile salt, an AMmonIum salt is preferred in viEw of tHe EAse oF HaNdlinG, safety, EAsE OF acQuIsItiOn, ANd Price. ammOnium acEtate is furTheR pReferred. AlteRNaTively, it is PreFerred to use tHe eLuent sUbStaNTiallY coNtainIng onlY Salts sOluble in oRgANic solVEnts as sALTs. as thE salt soluble in an oRGaNIc solvent, an aceTate is PrEFeRREd iN viEw of the easE oF handLIng, safeTY, eASE Of aCQuisition, and pRice. AmmoniuM AceTate or SoDiuM AcetatE is fuRtHEr pReferred.
The ResuLting inteRmediaTE can be cONverted Into thE deSirEd coMPoUnD by PuRIfiCAtIon OR moDificatiOn UsIng vaRiouS METHods, For ExamPle, orGanic chemical MetHods OR biOchemIcal mEthoDs Or comBinatiOns of ThEse.
The compound oF the Invention, Its PhArmAcOlogiCAlly acCepTabLe salt aNd solvaTE, or A sOLVAtE of the salt is usuallY aDMInIstered sYstemiCAlLy OR locally, OrAllY or pAREnterAlly. aS tHe dose, thE optimAL dOsE should Be DetermInEd aCcoRding TO oveRall juDgment baSed on COnditions, such aS The type of diseASe, THE sEVeriTy oF symptoms, thE age ANd boDy weIGhT of THe subJect rEcEIvINg treatment. The dose iS nOt restRicteD, but in adults, tHe usual daiLY DOse is 0.01 to 100 mG/kg oRAlLY, or 0.001 to 10 mg/kg parenTeralLy. The dose iS AdministEred oNce daily Or in dividED Doses, wheRe nEceSsaRy.
THE CoMpound of the inVENtioN, iTs pharmAcoLogicalLy aCcePtaBle SaLt and solvAte, or a soLvAtE oF tHe sAlt maY Be adminiStEreD iN anY form, SUch as oRal foRms iNcLuDIng A solid cOMpOSItioN, a LiQuid ComPoSitioN, and OTheR composItion, or paRenTEral FoRmS includIng injection, eXtErnally useD pRepAratioN, ANd supposItory. The most suitable forM Is selecTed AccorDing To need. A phArmAceutiCal COmposiTion coNtainInG at LEAst onE OF tHe cOmPounds of thE INveNtion, ThEir pHarmacoLogically acceptablE SalTs and solvates, Or sOlvaTES oF thE SaLTs cAn BE prEPAred by using carrIers, excipiEnTS aNd other addITivEs Used for OrdinarY pharMAceuticAl manufacTuring. ExaMpLes oF THe cArriers and ExcipienTs for prepARatioNS aRe lacTosE, magneSiUm sTearaTe, starCH, taLc, gelAtin, agAr, Pectin, AcaciA, oLive oil, sEsame oil, cacao butter, ethyLene glYcol, aNd oTher materIalS In cUstomary uSe.
As A solid compOsiTioN for oRal ADminiStraTIoN, taBLets, pIlls, CApsules, poWDeR, anD GRaNules are useD. iN SucH a solId cOMpositIon, aT least one active suBStance (active inGredIENt) iS miXEd wiTh At least one inerT diLuENT, such as lAcTose, mannitoL, glucose, HyDRoxypRopylcElluloSe
uent substantially contain ing only v olati lesal ts  assalt s. As the vola t ilesalt, an ammonium salt  is p re f erre d  i n vie w of th e  e a s e o fha ndl in g ,safet y,ease of  acquisiti on,  a nd price. Am m on ium acetat e i s further pr efe rred.Al ter n ative ly,  it i s pref e rred t o use the  e l uent s u bstanti a l ly  con taining only salt s  s o luble in organ ic sol ve n ts a s s alt s. As thesa lt so l uble in an o r gan i c solvent, an  acetate is pre ferred  i n v i ew ofthe e as e  of  handling,safe ty, easeof acq u isition ,  and pr ice. A mmo niu m ac e ta te  or  s o diu m  a cet a teis furth er  p refer red. T h e  res ult inginter mediate can b e c onve r ted  into  thedesi re d com poundby pu ri fication or mod ific ation usi ngva rio us  meth o ds, fo r e xam ple, or ganic c h emi ca l m et hods or biochemica lm e th ods or c ombina t io ns of these .The  com p o und o f th e  i nvention , itsp ha rm acologi ca lly ac ce pta ble  salt andsolvat e, or asolva t e of the salti s usually adm i ni s t er e d sy ste mically orloca l ly,oral l yorp arent erall y. As the dose, the optim al  doseshoul d be determin ed accordi n g to overa ll j u dg m ent based on c ondit ions, such as the t ype o f diseas e, the se v e rity ofsym pto ms,  th e ag e and body we i g ht o fthe sub jec t recei vin g t rea tme nt . The dos e is not  r es tr ic ted , but in adult s,  th eusu al da i ly dos e is0.01  t o1 00mg/kg o r al l y , or  0 .0 01 t o 1 0mg/kg  par e nte rally.The doseisa dmin is te red onc e daily or in  d ivided dos es , w here n e c essary.The compound of the inv e ntion,its  phar maco logically  ac ceptab les alt an d solv ate,or  as o lvate o fthe  s alt may be a dmi niste re d in  any fo rm, such as oral f o rms  including asol id c o m po sit i on ,  ali q uid c omposition, and  other com po s it ion, or pa r ent er al form s inclu dingi njectio n, extern ally used  p repa r a tio n, and sup pository . The mos t  suit a bl e for m i s sele ct edaccor ding t o  ne ed. A  pharm ac eutica l com po sition c ontaining at least oneof the  comp oun ds of the  in v ent ion, thei r ph armacologi cal lyaccep tab l e sal ts a n dsol v ates,  ors olvates o f  t hes a lt s can be pr e p a red  by u sin g  carri ers,  excipients and o t her additivesused f orord i nary  p harmaceuticalman uf a c turing.Ex amples of t he carri er s  andexcipi ents f or prep a r at i ons ar e la cto se, magne siu ms tearate ,st a rch, t alc,  g elatin , agar ,  pec t i n, acacia, olive  oil, s esame oil , cac ao  butter ,  eth ylene glyc ol, and oth er mat eria ls in  custom ar y use. 
As  a  solid com p osition f or or al admi ni stra tio n, tab lets , pills , ca ps ule s, powder , an d  g ra n ule s ar e use d.  Insuch a so l id compo sit i on, atle ast o ne act i ve s ubstance ( act ive i n g redient) i s  mix e dw ith a t leas t oneinert d i lue nt , suchasl a ctose, ma nnitol, g l uco se , hy droxypro py lcel lu los e
uent substantially_containing only_volatile salts as salts._As the_volatile_salt, an_ammonium_salt is preferred_in view of_the ease of handling,_safety, ease of_acquisition,_and price. Ammonium acetate is further preferred. Alternatively, it is preferred to use the_eluent_substantially containing_only_salts_soluble in organic solvents as_salts. As the salt soluble_in an_organic solvent, an acetate is preferred in view_of_the ease of_handling, safety, ease of acquisition, and price. Ammonium acetate_or sodium acetate is further preferred.
The_resulting intermediate can_be_converted_into the desired compound_by purification or modification using various_methods, for example, organic chemical methods_or biochemical methods or combinations of these.
The_compound of the invention, its pharmacologically_acceptable salt and solvate, or_a solvate_of the salt is usually_administered systemically or_locally, orally_or parenterally. As_the dose, the optimal dose should_be determined according_to overall judgment based on conditions,_such_as the type_of_disease,_the severity_of symptoms, the_age_and body_weight_of the subject receiving treatment. The_dose_is not restricted, but in adults, the_usual daily dose is_0.01_to 100 mg/kg orally,_or 0.001 to 10 mg/kg_parenterally. The dose is administered once_daily or_in divided_doses, where necessary.
The compound of the invention, its pharmacologically acceptable salt_and solvate, or a solvate of_the salt may be_administered in_any_form, such as_oral_forms including_a solid composition, a liquid composition, and_other composition,_or parenteral forms including injection, externally_used preparation, and suppository._The_most suitable form is selected according_to need. A pharmaceutical composition containing_at least one of the_compounds_of_the invention, their pharmacologically acceptable_salts and solvates, or solvates of_the salts can_be prepared by using carriers, excipients and_other_additives used for ordinary pharmaceutical manufacturing._Examples_of the carriers and excipients for_preparations_are_lactose, magnesium stearate, starch, talc,_gelatin, agar, pectin, acacia, olive oil,_sesame oil, cacao butter, ethylene glycol, and other materials_in customary use.
As_a solid composition for oral_administration,_tablets,_pills, capsules, powder, and granules are used. In such a_solid composition,_at least one_active substance (active ingredient) is mixed with at least one_inert diluent, such as lactose, mannitol, glucose,_hydroxypropylcellulose